Despite a substantial increase in consensus revenue growth forecasts and a notable reduction in future P/E, analysts have revised Supriya Lifescience’s fair value down from ₹843 to ₹800.
What's in the News
- Board meeting scheduled to approve unaudited financial results for the quarter ended June 30, 2025.
- Board to consider revisions to the Nomination and Remuneration Policy, Policy on Determination of Materiality of Events, and Code of Conduct for Insider Trading.
- Board recommended a final dividend of INR 1 per equity share (50% of face value), subject to shareholder approval at the Annual General Meeting.
Valuation Changes
Summary of Valuation Changes for Supriya Lifescience
- The Consensus Analyst Price Target has fallen from ₹843.00 to ₹800.00.
- The Consensus Revenue Growth forecasts for Supriya Lifescience has significantly risen from 19.5% per annum to 23.1% per annum.
- The Future P/E for Supriya Lifescience has significantly fallen from 34.83x to 29.03x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.